Trials / Completed
CompletedNCT00227279
A Trial of the ALK Grass Tablet in Subjects With Hayfever
A Randomized, Parallel-group, Double-blind, Placebo-controlled Phase III Trial Assessing the Efficacy and Safety of ALK Grass Tablet in Subjects With Seasonal Grass Pollen Induced Rhinoconjunctivitis
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 634 (actual)
- Sponsor
- ALK-Abelló A/S · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This trial is performed to assess the efficacy and safety of the ALK Grass tablet for treatment of grass pollen induced rhinoconjunctivitis (hayfever).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | ALK Grass tablet | Tablets, 75,000 SQ-T or matching placebo. Daily administration for 3 years |
Timeline
- Start date
- 2004-10-01
- Primary completion
- 2009-09-01
- Completion
- 2009-09-01
- First posted
- 2005-09-28
- Last updated
- 2013-01-29
Locations
1 site across 1 country: Denmark
Source: ClinicalTrials.gov record NCT00227279. Inclusion in this directory is not an endorsement.